异动解读|中国生物制药盘中下跌3.05%,两款乙肝创新药获突破性治疗认定

行情直击
Yesterday

10月27日,中国生物制药盘中下跌3.05%,报4.76港元,成交额2.12亿港元。

当日消息面上,公司旗下正大天晴自主研发的两款慢性乙肝创新药TQ-A3334及TQA3605获国家药监局药品审评中心纳入突破性治疗药物程序。

TQ-A3334为口服TLR7激动剂,目标为实现乙肝功能性治愈,正准备进入III期临床;TQA3605为核心蛋白变构调节剂,面向经治疗后仍存在低病毒水平患者,已进入III期临床。该进展反映公司在乙肝创新管线上的推进。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10